These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 2887407)

  • 1. SMS 201-995 improves glucose tolerance in insulin-treated type II diabetic patients.
    Candrina R; Coppini A; Graffeo M; Zuccato F; Giustina G
    Diabetes Care; 1987; 10(4):534-5. PubMed ID: 2887407
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of SMS 201-995 in non-insulin-dependent diabetes.
    Candrina R; Giustina G
    Clin Endocrinol (Oxf); 1987 Aug; 27(2):279-80. PubMed ID: 2889549
    [No Abstract]   [Full Text] [Related]  

  • 3. Postprandial glycaemic effects of a long-acting somatostatin analogue (octreotide) in non-insulin dependent diabetes mellitus.
    Williams G; Füessl HS; Burrin JM; Chilvers E; Bloom SR
    Horm Metab Res; 1988 Mar; 20(3):168-70. PubMed ID: 2898427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postprandial effects of SMS 201-995 on gut hormones and glucose tolerance.
    Williams G; Fuessl H; Kraenzlin M; Bloom SR
    Scand J Gastroenterol Suppl; 1986; 119():73-83. PubMed ID: 2876509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucose tolerance during long term treatment with a somatostatin analogue.
    Verschoor L; Lamberts SW; Uitterlinden P; Del Pozo E
    Br Med J (Clin Res Ed); 1986 Nov; 293(6558):1327-8. PubMed ID: 2878704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced postprandial hyperglycemia after subcutaneous injection of a somatostatin-analogue (SMS 201-995) in insulin-dependent diabetes mellitus.
    Spinas GA; Bock A; Keller U
    Diabetes Care; 1985; 8(5):429-35. PubMed ID: 2865093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of a long-acting somatostatin derivative SMS 201-995 (sandostatin) on glucose homeostasis in type I diabetes mellitus.
    Navascues I; Gil J; Pascau C; Senén D; del Pozo E; Serrano-Ríos M
    Horm Res; 1988; 29(2-3):92-4. PubMed ID: 2900205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Somatostatin analog SMS 201-995 and insulin needs in insulin-dependent diabetic patients studied by means of an artificial pancreas.
    Rios MS; Navascues I; Saban J; Ordoñez A; Sevilla F; Del Pozo E
    J Clin Endocrinol Metab; 1986 Nov; 63(5):1071-4. PubMed ID: 2876005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of SMS 201-995 in rapidly progressive diabetic retinopathy.
    Lee HK; Suh KI; Koh CS; Min HK; Lee JH; Chung H
    Diabetes Care; 1988 May; 11(5):441-3. PubMed ID: 2899019
    [No Abstract]   [Full Text] [Related]  

  • 10. Improvement of diabetes after treatment with somatostatin analogue SMS 201-995 in an acromegalic patient.
    Cantalamessa L; Catania A; Baldini M; Orsatti A
    Horm Metab Res; 1986 Nov; 18(11):790-1. PubMed ID: 2878866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term treatment of acromegaly with Sandostatin (SMS 201-995). Normalization of most anomalous growth hormone responses.
    Pieters GF; van Liessum PA; Smals AG; van Gennep JA; Benraad TJ; Kloppenborg PW
    Acta Endocrinol Suppl (Copenh); 1987; 286():9-18. PubMed ID: 2892339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of a new long-acting somatostatin analogue (SMS 201-995) on glycemic and hormonal profiles in insulin-treated type II diabetic patients.
    Candrina R; Giustina G
    J Endocrinol Invest; 1988; 11(7):501-7. PubMed ID: 3049768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist.
    Jørgensen JO; Feldt-Rasmussen U; Frystyk J; Chen JW; Kristensen LØ; Hagen C; Ørskov H
    J Clin Endocrinol Metab; 2005 Oct; 90(10):5627-31. PubMed ID: 16046586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of SMS 201-995 on intermediary metabolism and endocrine status in normal and diabetic humans.
    Johnston DG; Davies RR; Alberti KG; Miller M; Turner SJ; Watson M; Orskov H
    Am J Med; 1986 Dec; 81(6B):88-93. PubMed ID: 2879452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of postprandial hypotension with a somatostatin analogue (SMS 201-995).
    Hoeldtke RD; Boden G; O'Dorisio TM
    Am J Med; 1986 Dec; 81(6B):83-7. PubMed ID: 2879451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of growth hormone and somatomedin C by long-acting somatostatin analog SMS 201-995 in type I diabetes mellitus.
    Plewe G; Noelken G; Krause U; Beyer J; del Pozo E
    Horm Res; 1987; 27(1):7-12. PubMed ID: 2887504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [References for a blood glucose lowering effect of tritoqualine in insulin treated diabetic patients].
    Köbberling J; Cüppers HJ; Hintze G; Richter K; Rommelmann F; Tillil H
    Med Klin (Munich); 1988 Sep; 83(18):596-600. PubMed ID: 3054462
    [No Abstract]   [Full Text] [Related]  

  • 18. Glycemic profile in patients with acromegaly treated with somatostatin analogue.
    Valea A; Carsote M; Ghervan C; Georgescu C
    J Med Life; 2015; 8 Spec Issue(Spec Issue):82-6. PubMed ID: 26361517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Role of a prolonged-action analog of somatostatin SMS 201-995 in the therapy of type 2 diabetes mellitus].
    Candrina R; Giustina G
    Medicina (Firenze); 1988; 8(3):313-5. PubMed ID: 3231042
    [No Abstract]   [Full Text] [Related]  

  • 20. Acute effect of the somatostatin analogue SMS-201995 on plasma glucose and triglycerides in insulin-dependent diabetic patients.
    Malerbi DA; de-Camargo JW; Cesar FP; Wajchenberg BL
    Braz J Med Biol Res; 1992; 25(6):593-600. PubMed ID: 1342235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.